Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10222-10238

  Tung, Yu Tang ^a   Huang, Pin Wu ^a   Chou, Yu Ching ^a   Lai, Cheng Wei ^a   Wang, Hsiu Po ^a   Ho, Heng Chien ^b   Yen, Chih Ching ^a,b   Tu, Chih Yen ^a,b   Tsai, Tung Chou ^a   Yeh, Dah Cherng ^c   Wang, Jiun Long ^a,c   Chong, Kowit Yu ^d   Chen, Chuan Mu ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Magnetic resonance imaging (MRI); miRNA therapy; Pulmonary tumorigenesis; Transgenic mice; VEGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; MICRORNA 16; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2; MICRORNA; MIRN16 MICRORNA, HUMAN; ONCOPROTEIN; TRANSCRIPTOME; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOMA; ALPHA SMA GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHITIS; CANCER INHIBITION; CDC2 GENE; CLARA CELL; COLLAGEN ALPHA1 GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYCLIN B1 GENE; CYST; DNA MICROARRAY; EGFR GENE; EMBRYO; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HISTOPATHOLOGY; HVEGF-A16 GENE; IMMUNOHISTOCHEMISTRY; KDR GENE; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MICROARRAY ANALYSIS; MICROINJECTION; MMP9 GENE; MOUSE; MOUSE STRAIN; NONHUMAN; NRP 1 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TGF BETA1 GENE; TIMP1 GENE; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; CARCINOGENESIS; CHICK EMBRYO; DRUG SCREENING; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CHICK EMBRYO; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; MICRORNAS; ONCOGENE PROTEINS, FUSION; SIGNAL TRANSDUCTION; TRANSCRIPTOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929590499     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3390     Document Type: Article

References (44)

1. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. EUROCARE Working Group. EUROCARE-3:survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol. 2003; 5:S61-118.
2. World Health Organization. World Health Statistics 2006. Geneva, Switzerland: World Health Organization; 2006. Available at: http://www.who.int/whosis/whostat2006/ en/ index.html
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011; 61:69-90.
4. Carney DN. Lung cancer - time to move on from chemotherapy. N Engl J Med. 2002; 346:126-128.
5. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002; 1:49-52.
6. Rosell R, Monz M, Pifarre A, Ariza A, Sanchez JJ, Moreno I, et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res. 1996; 2:1083-1086.
7. Malkinson AM. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res. 1998; 24:541-555.
8. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol. 2008; 3:1173-1184.
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9:669-676.
10. Tammela T, Enholm B, Alitalo K, Pavvonen K. The biology of vascular endothelial growth factors. J Cardio Res. 2004; 65:550-563.
11. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, et al. Human vascular permeability factor: Isolation from U937 cells. J Biol Chem. 1989; 254:20017-20024.
12. Ferrara N. VEGF and the request for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2:795-803.
13. Gasparini G. The rationale and future potential of angiogenesis inhibitor in neoplasia. Drugs. 1999; 58:17-38.
14. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18:4-25.
15. Murphy G., Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, et al. Mechanisms for pro matrix metalloproteinase activation. Acta Pathol Microbiol Immun Scand. 1999; 107:38-44.
16. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol. 2003; 9:1144-1155.
17. Wicki A, Christofori G. The angiogenic switch in tumorigenesis. In: Tumor angiogenesis. Marme D, Fusenig N (eds.) Springer Berlin Heidelberg, New York. 2008; pp 67-88.
18. Hicks SM, Vassallo JD, Dieter MZ, Lewis CL, Whiteley LO, Fix AS, et al. Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology. 2003; 187:217-228.
19. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007; 62:179-213.
20. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358:2039-2049.
21. Fontanini G, Vignati S, Boldrini L, Chinè S, Silvestri V, Lucchi M, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res. 1997; 3:861-865.
22. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001; 19:432-441.
23. Zachary I. VEGF signalling: Integration and multi-tasking in endothelial cell biology. Biochem Soc Trans. 2003; 31:1171-1177.
24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355:2542-2550.
25. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil. J Clin Oncol. 2009; 27:1227-1234.
26. Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat Rec. 2001; 265:85-100.
27. Kennel SJ, Davis IA, Branning J, Pan H, Kabalka GW, Paulus MJ. High resolution computed tomography and MRI for monitoring lung tumor growth in mice undergoing radioimmunotherapy: Correlation with histology. Med. Phys. 2000; 27:1101-1107.
28. Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J. 2008; 49:17-26.
29. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006; 1:e116.
30. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009; 113:6669-6680.
31. Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 2013; 34:426-35.
32. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010; 18:181-187.
33. Liu HC, Pai SY, Cheng WT, Chen HL, Tsai TC, Yang SH, et al. Ingestion of milk containing the Dp2 peptide, a dust mite allergen, protects mice from allergic airway inflammation and hyper-responsiveness. Allergy Asthma Clin Immunol. 2013; 9:21.
34. Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008; 26:2882-2889.
35. Yen CC, Lim CY, Chong KY, Tsai TC, Shen CJ, Lim MF, et al. Lactoferrin as a natural regimen for selective decontamination of the digestive tract: recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonates from pathogenic challenge in the gastrointestinal tract. J Infect Dis. 2009; 199:590-598.
36. Yen CC, Lai YW, Chen HL, Lai CW, Lin CY, Chen W, et al. Aerosolized human extracellular superoxide dismutase prevents hyperoxia-induced lung injury. PLoS One. 2011; 6:e26870.
37. Lai CW, Chen HL, Lin KY, Liu FC, Chong KY, Cheng WT, et al. FTSJ2, a heat shock-inducible mitochondrial protein, suppresses cell invasion and migration. PLoS One. 2014; 9:e90818.
38. Tung YT, Chen HL, Lee CY, Chou YC, Lee PY, Tsai HC, et al. Active component of danshen (Salvia miltiorrhiza Bunge), tanshinone I, attenuates lung tumorigenesis via inhibitions of VEGF, Cyclin, A, and Cyclin B expressions. Evid Based Complement Alternat Med. 2013; 2013:319247.
39. Huang JT, Tseng CP, Liao MH, Lu SC, Yeh WZ, Sakamoto N, et al. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase. J Virol. 2013; 87:4994-5004.
40. Richardson M., Singh G. Observations on the use of the avian chorioallantoic membrane (CAM) model in investigations into angiogenesis. Curr Drug Targets-Cardiovasc Hematol Disord. 2003; 3:155-185.
41. Wen ST, Chen W, Chen HL, Lai CW, Yen CC, Lee KH, et al. Amniotic fluid stem cells from EGFP transgenic mice attenuate hyperoxia-induced acute lung injury. PLoS One. 2013; 8:e75383.
42. Chen HL, Yen CC, Wang SM, Tsai TC, Lai ZL, Sun JY, et al. Aerosolized bovine lactoferrin reduces lung injury and fibrosis in mice exposed to hyperoxia. Biometals. 2014; 27:1057-1068.
43. Cheng PH, Li CL, Chang YF, Tsai SJ, Lai YY, Chan AW, et al. miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet. 2013; 93:306-312.
44. Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Singh M. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res. 2006; 23:2094-2106.